The IQ Working Group has defined a pragmatic risk-based approach to audit trail review, where it is only required for high impact GxP data.
Julie Lippke
Advertisement
Julie Lippke, analytical research and development at Pfizer Inc., Groton, CT
Articles by Julie Lippke
Sponsors should consider best practices for maintaining data generated during sample analysis and instrument maintenance.
A data-integrity risk assessment tool has been developed for use with standalone R&D data-acquisition and processing software.
Advertisement
Latest Updated Articles
A Harmonized Approach to Performing a Risk-Based Audit Trail ReviewSeptember 2nd 2022
Assessing Data Integrity Risks in an R&D EnvironmentAugust 2nd 2020
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
CDMOs, OEMs, and Used Equipment Resellers are Joining Forces to Onshore Pharmaceutical Manufacturing
2
Meeting Tomorrow's Market Requirements: Vetter's Perspective on the Future of Fill & Finish
3
Why Drug Shortages Average 5+ Years: PharmTech Explained
4
ADCs, Degraders, Agonists: 4 Deals CMC Teams Should Track
5